Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations

Nakao, Makoto; Muramatsu, Hideki; Kagawa, Yusuke; Suzuki, Yuto; Sakai, Yusuke; Kurokawa, Ryota; Fujita, Kohei; Sato, Hisaaki

doi:10.21873/anticanres.11753

Cited by 8 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This index was originally studied to demonstrate the relation with postoperative complications and prognosis for patients affected by oesophageal carcinoma. 16 A low PNI level has been subsequently correlated with a worse outcome in patients with hepatocellular carcinoma, 17 18 lung cancer, 19 bladder cancer 20 and other solid tumours. As regards HNSCC a low PNI has been shown to be a predictor of poor survival, 21 and it has been associated with severe radiotherapy-induced adverse events in a small series of patients.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer

et al. 2018

View full text Add to dashboard Cite

BackgroundLocally advanced head and neck squamous cell carcinoma (LAHNSCC) is a heterogeneous disease in which better predictive and prognostic factors are needed. Apart from TNM stage, both systemic inflammation and poor nutritional status have a negative impact on survival.MethodsWe retrospectively analysed two independent cohorts of a total of 145 patients with LAHNSCC treated with induction chemotherapy followed by concurrent chemoradiotherapy at two different academic institutions. Full clinical data, including the Prognostic Nutritional Index (PNI), neutrophil to lymphocyte ratio and derived neutrophil to lymphocyte ratio, were analysed in a training cohort of 50 patients. Receiver operating characteristic curve analysis was used to establish optimal cut-off. Univariate and multivariate analyses of prognostic factors for overall survival (OS) were performed. Independent predictors of OS identified in multivariate analysis were confirmed in a validation cohort of 95 patients.ResultsIn the univariate analysis, low PNI (PNI<45) (p=0.001), large primary tumour (T4) (p=0.044) and advanced lymph node disease (N2b-N3) (p=0.025) were significantly associated with poorer OS in the validation cohort. The independent prognostic factors in the multivariate analysis for OS identified in the training cohort were dRNL (p=0.030) and PNI (p=0.042). In the validation cohort, only the PNI remained as independent prognostic factor (p=0.007).ConclusionsPNI is a readily available, independent prognostic biomarker for OS in LAHNSCC. Adding PNI to tumour staging could improve individual risk stratification of patients with LAHNSCC in future clinical trials.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The patient will have severe mental pain, depression, anxiety, and fear, and the patient's quality of life will be greatly reduced. The main cause of lung cancer is smoking [ 3 , 4 ]. Chronic obstructive pulmonary disease (COPD) is a common respiratory condition among the elderly that is linked to lung cancer incidence and patient symptom reports.…”

Section: Introductionmentioning

confidence: 99%

Correlation between the Treg/Thl7 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease

Wang

She

Gao

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. It was to explore the correlation between regulatory T cells (Treg)/T helper cell 17 (Thl7) and the efficacy of receiving a programmed death protein-1 (PD-1) monoclonal antibody (mAb) in patients with advanced non-small-cell lung cancer (NSCLC) complicated with chronic obstructive pulmonary disease (COPD). Methods. The research subjects were 82 patients who were clinically evaluated and treated in the Respiratory Department of Suqian Hospital connected with Xuzhou Medical University from January to December 2021. All of the patients were given PD-1 immunotherapy, and 50 healthy people were chosen as the control group. Classification was carried out according to tumor type and tumor stage. The levels of Th17 and Treg/Th17 in the peripheral blood of patients with different tumor-node-metastasis (TNM) stages and different types were compared, and the immune function, lung function (forced expiratory volume in one second/forced vital capacity (FEV1%/FVC), FEV1%, and FVC), and changes in inflammatory factors were compared before and after treatment. The levels of interleukin (IL)-17, IL-6, tumor necrosis factor (TNF)-α, and transforming growth factor (TGF)-β were compared between the two groups. The correlation between Th17 cells and Treg cells in the peripheral blood of patients with NSCLC complicated with COPD was analyzed. Results. After treatment, the levels of IL-17, IL-6, TNF-α, and TGF-β in patients with NSCLC combined with COPD were notably superior to those in the control group ( P < 0.05 ). The immune function and lung function of the patients were improved after treatment. There were 43 cases of squamous cell carcinoma, 30 cases of adenocarcinoma, and 9 cases of large cell carcinoma. The proportion of Th17 cells to CD4+ T cells in the blood of the three types of patients and the proportion of CD4+CD25HiCD127Lo regulatory T cells to CD4+ lymphocyte cells in Treg cells showed no considerable difference among the different case types ( P > 0.05 ). No considerable difference was indicated in Treg/Th17 in peripheral blood between stage IIIB and stage IV lung cancer patients ( P > 0.05 ). A positive linear correlation was revealed between Th17 cells and Treg cells in the peripheral blood of patients with NSCLC combined with COPD, R = 0.26 , P = 0.039 . Conclusion. Treg and Th17 cells were shown to be much higher in lung cancer patients with COPD, which could lead to immunosuppression and tumor growth. PD-1 therapy for NSCLC has demonstrated efficacy and can improve patients’ immunological state while being extremely safe.

show abstract

“…Similarly, one should consider PNI as a predictor of response to immunotherapy in HNC. Recently, low pretreatment PNI has been associated to early termination of nivolumab in patients with non-small cell lung cancer 11 ; moreover, in a heterogeneous population of patients treated with immunotherapy, the Gustave Roussy Immune Score, based on albumin, LDH and NLR, showed to be prognostic for survival. 12 Therefore, the advantages of PNI as an easy and reproducible biomarker reflecting both the underlying immune status and the host inflammatory response should be better exploited also in the immunotherapeutic arena.…”

mentioning

confidence: 99%

Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer?

Bossi

2018

ESMO Open

View full text Add to dashboard Cite

Immunological Status May Predict Response to Nivolumab in Non-small Cell Lung Cancer without Driver Mutations

Abstract: High NLR and low PNI were associated with early termination of nivolumab monotherapy, suggesting they might be useful biomarkers for treatment selection.

Cited by 8 publications

References 15 publications

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer

Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer

Correlation between the Treg/Thl7 Index and the Efficacy of PD-1 Monoclonal Antibody in Patients with Advanced Non-Small-Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease

Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer?

Contact Info

Product

Resources

About